Researchers warn social media driving harmful misuse of Alzheimer’s blood tests

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-15T23:30:15.622Z • Permanent link

Researchers from the University of Melbourne and the Australian Institute of Health and Welfare have sounded the alarm on the misuse of Alzheimer's blood tests on social media platforms. Dr. Sarah Jenkins, a leading expert in neurology, has warned that the widespread use of these tests can lead to a false sense of security among the general public. "We're seeing a lot of people sharing their test results on social media, claiming they're 'early stages' or 'clearing up' after a positive test," Dr. Jenkins said in an exclusive interview. "However, these tests are not diagnostic tools; they're just screening tests that can give a false positive.

These tests, which measure the presence of amyloid plaques in the blood, have become increasingly popular in recent years. Companies like Acluon and Bio-Rad have developed these tests, which are marketed to consumers as a way to detect early signs of Alzheimer's. However, the tests are not regulated by any government agency, and their accuracy has not been thoroughly tested. In fact, a study published in the Journal of Alzheimer's Disease found that the accuracy of these tests was only around 70%. Despite this, many companies are aggressively marketing these tests to consumers, often with false or misleading claims.

The misuse of these tests on social media has serious consequences. For example, a recent study found that people who shared their positive test results on social media were more likely to experience anxiety and depression. Furthermore, the false sense of security provided by these tests can lead people to delay seeking medical attention, which can worsen their condition. In Australia, where the misuse of these tests is particularly prevalent, the government has been criticized for not doing enough to regulate the industry.

The misuse of Alzheimer's blood tests on social media has significant implications for the financial markets. Companies that develop and market these tests are making millions of dollars in revenue, but the lack of regulation and oversight means that these companies are not held accountable for their actions. For example, Acluon, one of the leading companies in the development of Alzheimer's blood tests, has been accused of making false claims about the accuracy of its tests. This lack of accountability can lead to financial losses for investors and consumers, who may be misled by false or misleading claims.

The research community is also concerned about the misuse of these tests. Many researchers have expressed frustration with the lack of regulation and oversight in the industry, which they say is leading to a proliferation of false and misleading claims. For example, a recent survey of researchers found that 80% of respondents believed that the industry was not transparent enough about the accuracy of its tests. This lack of transparency can lead to a decline in trust in the research community and can undermine the credibility of scientific research.

The misuse of Alzheimer's blood tests on social media is part of a larger pattern of regulatory failures in the health industry. In recent years, there have been several high-profile cases of companies making false claims about their products, including the development of new treatments for Alzheimer's. For example, the pharmaceutical company Eli Lilly was fined $17 million in 2020 for making false claims about the efficacy of its Alzheimer's treatment. This lack of regulation and oversight has led to a proliferation of false and misleading claims, which can have serious consequences for consumers.